Wall Street Analysts Adjust ROKU Ratings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16h ago
0mins
Should l Buy DOCS?
Source: Benzinga
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, reflecting varying market perceptions that could influence investor decisions and market sentiment.
- Overview of Ratings Update: While specific upgrades or downgrades are not detailed, such changes in analyst ratings typically have a direct impact on stock prices, prompting investors to stay alert for further developments.
- Expected Market Reaction: The adjustments in analyst ratings may lead to short-term volatility in ROKU stock, and investors should consider the significance of these changes in their investment strategies to make informed decisions.
- Source Information: This rating change information is provided by Benzinga, highlighting the critical role analysts play in the market and their potential impact on investor decision-making.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 62.75 USD with a low forecast of 50.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
10 Buy
4 Hold
1 Sell
Moderate Buy
Current: 33.320
Low
50.00
Averages
62.75
High
82.00
Current: 33.320
Low
50.00
Averages
62.75
High
82.00
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DOMIXITY STOCK PLUNGES 34% IN PREMARKET TRADING FOLLOWING Q3 RESULTS
- Domicity Shares Decline: Domicity shares have fallen by 34% following the release of their Q3 results.
- Market Reaction: The significant drop in share value indicates a negative market reaction to the company's financial performance.
See More
Doximity Reports Strong Q3 2026 Earnings Amid Budget Uncertainties
- Significant Revenue Growth: Doximity reported Q3 revenue of $185.1 million, reflecting a 10% year-over-year increase and exceeding the high end of guidance by 2%, indicating strong performance and stable market demand in the healthcare sector.
- Innovative User Engagement: The company surpassed 3 million registered users, with 720,000 unique active prescribers, demonstrating Doximity's expanding influence among physicians and healthcare professionals, thereby enhancing its competitive position in the market.
- High AI Product Adoption: Over 300,000 unique prescribers utilized Doximity's AI products, with DocsGPT preferred at more than twice the rate of competitors, showcasing the company's leadership in AI and its potential for future growth.
- Cautious Future Outlook: While Q4 2026 revenue is expected to grow by 4%, management remains cautious due to policy uncertainties and increased AI infrastructure investments, emphasizing the strategy to leverage delayed client budget releases to drive future growth.
See More
Molina Healthcare Stock Plummets 29% After Earnings Miss
- Unexpected Quarterly Loss: Molina Healthcare reported an unexpected quarterly loss, causing its stock to plummet 29% in a single day, marking the largest drop since 2012 and indicating significant challenges in profitability.
- Weak 2026 Outlook: The company issued a weak earnings outlook for 2026, which may undermine investor confidence and further pressure the stock price, reflecting market concerns about its future growth potential.
- Strong Overall Market Performance: Despite Molina Healthcare's stock decline, the Dow Jones Industrial Average surged nearly 2% on Friday, reaching a new all-time high, indicating a market preference for value stocks that may overshadow individual stock weaknesses.
- Small Caps Outperform: Small caps showed outstanding performance on Friday, with the Russell 2000 index soaring over 3%, suggesting increased investor confidence in smaller companies, contrasting sharply with Molina's performance.
See More
Wall Street Analysts Adjust ROKU Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, reflecting varying market perceptions that could influence investor decisions and market sentiment.
- Overview of Ratings Update: While specific upgrades or downgrades are not detailed, such changes in analyst ratings typically have a direct impact on stock prices, prompting investors to stay alert for further developments.
- Expected Market Reaction: The adjustments in analyst ratings may lead to short-term volatility in ROKU stock, and investors should consider the significance of these changes in their investment strategies to make informed decisions.
- Source Information: This rating change information is provided by Benzinga, highlighting the critical role analysts play in the market and their potential impact on investor decision-making.
See More
Doximity Shares Plunge 24% After Q3 Earnings Miss Expectations
- Earnings Beat but Cautious Guidance: Doximity's Q3 sales and EPS exceeded Wall Street expectations; however, management's guidance for only 4% revenue growth in Q4 spooked investors, leading to a 24% drop in stock price.
- Sales Growth Slowdown: The company's sales growth decelerated from 23% in Q3 last year to 10% this year, raising concerns among investors about future performance, particularly amid intensifying market competition.
- Decline in Net Income: Net income fell from $75 million in Q3 2025 to $62 million this year, primarily due to a 27% increase in marketing expenses and heavy investments in AI infrastructure, indicating short-term pressure on profitability.
- Promising AI Product Outlook: While current AI spending is a financial headwind, over 100 top U.S. health systems have adopted Doximity's AI products, and as the company fully launches its commercial AI suite later this year, growth rates and margins are expected to improve.
See More
Wells Fargo Cuts Doximity Price Target to $45 Amid Regulatory Pressures
- Price Target Adjustment: Wells Fargo has lowered Doximity's price target from $55 to $45 while maintaining an 'Overweight' rating, reflecting a cautious outlook on the company's future performance amid reduced upfront commitments from pharmaceutical clients.
- Revenue Forecast Decline: Doximity expects Q4 revenue to range between $143 million and $144 million, a significant drop from $185.1 million reported in Q3, indicating pressures from slowed market growth and elongated sales cycles that could impact investor confidence.
- Stock Price Volatility: Doximity's shares plummeted 35% in pre-market trading on Friday, and if this level holds after the opening bell, it will mark the lowest point since November 2023, reflecting market concerns over the company's outlook and regulatory pressures.
- Client Budget Uncertainty: During a call with analysts, Doximity noted that client uncertainty regarding policy changes led to a lower percentage of annual budgets being deployed upfront, with many deals typically signed by December 31 being delayed into fiscal Q4, impacting the company's revenue growth potential.
See More
DOMIXITY STOCK PLUNGES 34% IN PREMARKET TRADING FOLLOWING Q3 RESULTS
- Domicity Shares Decline: Domicity shares have fallen by 34% following the release of their Q3 results.
- Market Reaction: The significant drop in share value indicates a negative market reaction to the company's financial performance.
See More
Doximity Reports Strong Q3 2026 Earnings Amid Budget Uncertainties
- Significant Revenue Growth: Doximity reported Q3 revenue of $185.1 million, reflecting a 10% year-over-year increase and exceeding the high end of guidance by 2%, indicating strong performance and stable market demand in the healthcare sector.
- Innovative User Engagement: The company surpassed 3 million registered users, with 720,000 unique active prescribers, demonstrating Doximity's expanding influence among physicians and healthcare professionals, thereby enhancing its competitive position in the market.
- High AI Product Adoption: Over 300,000 unique prescribers utilized Doximity's AI products, with DocsGPT preferred at more than twice the rate of competitors, showcasing the company's leadership in AI and its potential for future growth.
- Cautious Future Outlook: While Q4 2026 revenue is expected to grow by 4%, management remains cautious due to policy uncertainties and increased AI infrastructure investments, emphasizing the strategy to leverage delayed client budget releases to drive future growth.
See More
Molina Healthcare Stock Plummets 29% After Earnings Miss
- Unexpected Quarterly Loss: Molina Healthcare reported an unexpected quarterly loss, causing its stock to plummet 29% in a single day, marking the largest drop since 2012 and indicating significant challenges in profitability.
- Weak 2026 Outlook: The company issued a weak earnings outlook for 2026, which may undermine investor confidence and further pressure the stock price, reflecting market concerns about its future growth potential.
- Strong Overall Market Performance: Despite Molina Healthcare's stock decline, the Dow Jones Industrial Average surged nearly 2% on Friday, reaching a new all-time high, indicating a market preference for value stocks that may overshadow individual stock weaknesses.
- Small Caps Outperform: Small caps showed outstanding performance on Friday, with the Russell 2000 index soaring over 3%, suggesting increased investor confidence in smaller companies, contrasting sharply with Molina's performance.
See More
Wall Street Analysts Adjust ROKU Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on ROKU stock, reflecting varying market perceptions that could influence investor decisions and market sentiment.
- Overview of Ratings Update: While specific upgrades or downgrades are not detailed, such changes in analyst ratings typically have a direct impact on stock prices, prompting investors to stay alert for further developments.
- Expected Market Reaction: The adjustments in analyst ratings may lead to short-term volatility in ROKU stock, and investors should consider the significance of these changes in their investment strategies to make informed decisions.
- Source Information: This rating change information is provided by Benzinga, highlighting the critical role analysts play in the market and their potential impact on investor decision-making.
See More
Doximity Shares Plunge 24% After Q3 Earnings Miss Expectations
- Earnings Beat but Cautious Guidance: Doximity's Q3 sales and EPS exceeded Wall Street expectations; however, management's guidance for only 4% revenue growth in Q4 spooked investors, leading to a 24% drop in stock price.
- Sales Growth Slowdown: The company's sales growth decelerated from 23% in Q3 last year to 10% this year, raising concerns among investors about future performance, particularly amid intensifying market competition.
- Decline in Net Income: Net income fell from $75 million in Q3 2025 to $62 million this year, primarily due to a 27% increase in marketing expenses and heavy investments in AI infrastructure, indicating short-term pressure on profitability.
- Promising AI Product Outlook: While current AI spending is a financial headwind, over 100 top U.S. health systems have adopted Doximity's AI products, and as the company fully launches its commercial AI suite later this year, growth rates and margins are expected to improve.
See More
Wells Fargo Cuts Doximity Price Target to $45 Amid Regulatory Pressures
- Price Target Adjustment: Wells Fargo has lowered Doximity's price target from $55 to $45 while maintaining an 'Overweight' rating, reflecting a cautious outlook on the company's future performance amid reduced upfront commitments from pharmaceutical clients.
- Revenue Forecast Decline: Doximity expects Q4 revenue to range between $143 million and $144 million, a significant drop from $185.1 million reported in Q3, indicating pressures from slowed market growth and elongated sales cycles that could impact investor confidence.
- Stock Price Volatility: Doximity's shares plummeted 35% in pre-market trading on Friday, and if this level holds after the opening bell, it will mark the lowest point since November 2023, reflecting market concerns over the company's outlook and regulatory pressures.
- Client Budget Uncertainty: During a call with analysts, Doximity noted that client uncertainty regarding policy changes led to a lower percentage of annual budgets being deployed upfront, with many deals typically signed by December 31 being delayed into fiscal Q4, impacting the company's revenue growth potential.
See More
